BridgeBio Oncology Therapeutics (BBOT) Return on Capital Employed (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Return on Capital Employed of 35.89% for Q1 2026, down 32.56% sequentially from 27.08% in Q4 2025, and up 51.0% YoY from 23.77% in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Return on Capital Employed (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Return on Capital Employed for 3 years, with the latest figure at 35.89% in Q1 2026.
- Quarterly Return on Capital Employed rose 51.0% year-over-year to 35.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.89% (up 51.0% YoY) and the FY2025 annual result came in at 53.75%, up 7514.0% from the prior year.
- Return on Capital Employed slipped to 35.89% in Q1 2026 per BBOT's latest filing, from 27.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 26.31% in Q4 2024 and troughed at 36.4% in Q1 2025.
- A 3-year average of 31.8% and a median of 32.57% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 77 bps in 2025, then soared 51 bps in 2026.
- Over 3 years, Return on Capital Employed stood at 26.31% in 2024, then declined by 3 bps to 27.08% in 2025, then slumped by 33 bps to 35.89% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 35.89%, 27.08%, and 31.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -57.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.58% |
| Mar 31, 2026 | -35.89% |
| Dec 31, 2025 | -27.08% |
| Sep 30, 2025 | -31.21% |
| Jun 30, 2025 | -33.94% |
| Mar 31, 2025 | -36.40% |
| Dec 31, 2024 | -26.31% |